enzalutamide + bicalutamide
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Neoplasms
Conditions
Prostatic Neoplasms
Trial Timeline
Mar 22, 2011 → Nov 8, 2017
NCT ID
NCT01288911About enzalutamide + bicalutamide
enzalutamide + bicalutamide is a phase 2 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01288911. Target conditions include Prostatic Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01664923 | Phase 2 | Completed |
| NCT01288911 | Phase 2 | Completed |
Competing Products
20 competing products in Prostatic Neoplasms